Horizon begins phase four clinical trial of Genmab drug

Horizon Therapeutics enters phase four clinical trial of the drug Tepezza to learn more about its effects on patients with chronic Graves' ophthalmopathy. The company has reaped millions from the already FDA-approved drug.
Photo: Lars Møller / Genmab / PR
Photo: Lars Møller / Genmab / PR

The drug Tepezza has already been celebrated by the pharmaceutical industry as the first FDA-approved drug for the treatment of thyroid eye disease, also known as Graves' ophthalmopathy. The company behind the drug, Horizon Therapeutics, is now eager to better understand the long-term use of the drug.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading